Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in asian patients with newly diagnosed al amyloidosis: subgroup analysis of andromeda

HIGHLIGHTS

• who: Kenshi Suzuki from the (UNIVERSITY) have published the research: Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA, in the Journal: (JOURNAL) of February/14,/2020
• what: The authors report a subgroup analysis of Asian patients (Japan; Korea; China) from ANDROMEDA. The study was approved by independent ethics committees or institutional review boards at each site and was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical Practice guidelines.
• how: The study design and analyses were . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.